Last reviewed · How we verify
Tislelizumab（adjuvant）
Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of T cells that helps to regulate the immune response.
Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of T cells that helps to regulate the immune response. Used for Adjuvant treatment of esophageal squamous cell carcinoma, Adjuvant treatment of colorectal cancer.
At a glance
| Generic name | Tislelizumab（adjuvant） |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, tislelizumab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on the surface of tumor cells. This blockade prevents the inhibition of T-cell activation and proliferation, allowing the immune system to recognize and attack cancer cells more effectively.
Approved indications
- Adjuvant treatment of esophageal squamous cell carcinoma
- Adjuvant treatment of colorectal cancer
Common side effects
- fatigue
- diarrhea
- nausea
- pyrexia
- hypothyroidism
- decreased appetite
- dyspnea
- cough
- headache
- muscle weakness
Key clinical trials
- Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC (PHASE2)
- A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy (PHASE2)
- Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma (PHASE2)
- Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer (PHASE2)
- Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma (PHASE3)
- Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma (PHASE3)
- Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: